Tvardi Therapeutics Inc. unveils corporate presentation on STAT3 inhibitor development for fibrosis-driven diseases

Reuters

Jan 16

<a href="https://laohu8.com/S/TVRD">Tvardi Therapeutics Inc</a>. unveils corporate presentation on STAT3 inhibitor development for fibrosis-driven diseases

Tvardi Therapeutics Inc. has released a new corporate presentation highlighting progress in its development of therapies targeting STAT3 biology for fibrosis-driven diseases and cancers. The company reports demonstrated target engagement and disease modification across animal models, as well as observed reductions in fibrosis and inflammation markers in clinical studies. Tvardi’s lead program, TTI-101, is being evaluated for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma $(HCC)$, with additional data from ongoing trials expected in the near term. The presentation also notes the advancement of TTI-109, a prodrug designed to enhance delivery and tolerability of STAT3 inhibition, currently in a Phase 1 trial with healthy volunteers. You can access the full presentation through the link below.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief on January 16, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Trading app for stocks, options & ETFs","description":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","keywords":"tiger brokers,tiger brokers au,tiger brokers australia,tiger trade,tiger trading,australia stock platform,US option,US stocks,stocks and options,australian trading platform,online broker australia,stock trading apps,mobile trading app,desktop trading,chess sponsored brokers,share trading platform","social":{"ogDescription":"Invest in US, ASX, HK, China A-shares, ETFs & options with Tiger Brokers, Australia's trusted stock trading app!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2603934475"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"AUS","license":"TBAU","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2603934475\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2603934475?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-16 08:04","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2603934475","market":"nz","top_or_hot":-1,"title":"Tvardi Therapeutics Inc. unveils corporate presentation on STAT3 inhibitor development for fibrosis-driven diseases","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TVRD\">Tvardi Therapeutics Inc</a>. unveils corporate presentation on STAT3 inhibitor development for fibrosis-driven diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tvardi <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has released a new corporate presentation highlighting progress in its development of therapies targeting STAT3 biology for fibrosis-driven diseases and cancers. The company reports demonstrated target engagement and disease modification across animal models, as well as observed reductions in fibrosis and inflammation markers in clinical studies. Tvardi’s lead program, TTI-101, is being evaluated for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma <a href=\"https://laohu8.com/S/HCC\">$(HCC)$</a>, with additional data from ongoing trials expected in the near term. The presentation also notes the advancement of TTI-109, a prodrug designed to enhance delivery and tolerability of STAT3 inhibition, currently in a Phase 1 trial with healthy volunteers. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief on January 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Tvardi Therapeutics Inc. unveils corporate presentation on STAT3 inhibitor development for fibrosis-driven diseases</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTvardi Therapeutics Inc. unveils corporate presentation on STAT3 inhibitor development for fibrosis-driven diseases\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-16 08:04</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/TVRD\">Tvardi Therapeutics Inc</a>. unveils corporate presentation on STAT3 inhibitor development for fibrosis-driven diseases\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        Tvardi <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Inc. has released a new corporate presentation highlighting progress in its development of therapies targeting STAT3 biology for fibrosis-driven diseases and cancers. The company reports demonstrated target engagement and disease modification across animal models, as well as observed reductions in fibrosis and inflammation markers in clinical studies. Tvardi’s lead program, TTI-101, is being evaluated for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma <a href=\"https://laohu8.com/S/HCC\">$(HCC)$</a>, with additional data from ongoing trials expected in the near term. The presentation also notes the advancement of TTI-109, a prodrug designed to enhance delivery and tolerability of STAT3 inhibition, currently in a Phase 1 trial with healthy volunteers. You can access the full presentation through the link below.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief on January 16, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TVRD","symbol_name":"Tvardi Therapeutics Inc","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260116:nNDLbkMQfs:1","article_id":"2603934475","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2603934475","pubTimestamp":1768521893,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Tvardi Therapeutics Inc. has released a new corporate presentation highlighting progress in its development of therapies targeting STAT3 biology for fibrosis-driven diseases and cancers. The company reports demonstrated target engagement and disease modification across animal models, as well as observed reductions in fibrosis and inflammation markers in clinical studies. Tvardi’s lead program, TTI-101, is being evaluated for idiopathic pulmonary fibrosis  and hepatocellular carcinoma , with additional data from ongoing trials expected in the near term. The presentation also notes the advancement of TTI-109, a prodrug designed to enhance delivery and tolerability of STAT3 inhibition, currently in a Phase 1 trial with healthy volunteers. You can access the full presentation through the link below.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TVRD":"Tvardi Therapeutics Inc","BK4007":"制药"},"translate_title":"Tvardi Therapeutics Inc.公布了针对纤维化驱动疾病的STAT3抑制剂开发的公司演示","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVRD":0.9},"content_text":"Tvardi Therapeutics Inc. unveils corporate presentation on STAT3 inhibitor development for fibrosis-driven diseases\n    \n\n        Tvardi Therapeutics Inc. has released a new corporate presentation highlighting progress in its development of therapies targeting STAT3 biology for fibrosis-driven diseases and cancers. The company reports demonstrated target engagement and disease modification across animal models, as well as observed reductions in fibrosis and inflammation markers in clinical studies. Tvardi’s lead program, TTI-101, is being evaluated for idiopathic pulmonary fibrosis (IPF) and hepatocellular carcinoma $(HCC)$, with additional data from ongoing trials expected in the near term. The presentation also notes the advancement of TTI-109, a prodrug designed to enhance delivery and tolerability of STAT3 inhibition, currently in a Phase 1 trial with healthy volunteers. You can access the full presentation through the link below.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Tvardi Therapeutics Inc. published the original content used to generate this news brief on January 16, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}